These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1970263)

  • 1. The myasthenic syndrome: anaesthesia in a patient treated with 3.4 diaminopyridine.
    Telford RJ; Hollway TE
    Br J Anaesth; 1990 Mar; 64(3):363-6. PubMed ID: 1970263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
    Molgó J; Guglielmi JM
    Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
    Sanders DB
    Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome.
    Boerma CE; Rommes JH; van Leeuwen RB; Bakker J
    J Toxicol Clin Toxicol; 1995; 33(3):249-51. PubMed ID: 7760450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for Lambert-Eaton myasthenic syndrome.
    Keogh M; Sedehizadeh S; Maddison P
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
    Sanders DB; Howard JF; Massey JM
    Ann N Y Acad Sci; 1993 Jun; 681():588-90. PubMed ID: 8357206
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
    Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ
    Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lambert Eaton syndrome: autonomic neuropathy and inappropriate antidiuretic hormone secretion in a patient with small cell carcinoma of the lung.
    Manji H; Schwartz MS; McKeran RO
    J Neurol; 1990 Aug; 237(5):324-5. PubMed ID: 2172471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
    Kim DS; Claussen GC; Oh SJ
    Muscle Nerve; 1998 Aug; 21(8):1107-8. PubMed ID: 9655139
    [No Abstract]   [Full Text] [Related]  

  • 11. [Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine].
    Morata C; Alfaro A; Chumillas MJ; Montalar J
    Med Clin (Barc); 1995 Feb; 104(4):156. PubMed ID: 7898163
    [No Abstract]   [Full Text] [Related]  

  • 12. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine.
    Sadeh M; River Y; Argov Z
    Muscle Nerve; 1997 Jun; 20(6):735-9. PubMed ID: 9149081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].
    Matsushima M; Yaguchi H; Kishimoto R; Tsuji S; Yabe I; Sasaki H; Nakadate M; Shiraishi H; Motomura M
    Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1709-11. PubMed ID: 17802724
    [No Abstract]   [Full Text] [Related]  

  • 14. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.
    Tim RW; Massey JM; Sanders DB
    Neurology; 2000 Jun; 54(11):2176-8. PubMed ID: 10851390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3,4-diaminopyridine in the treatment of myasthenic syndromes. Practical aspects].
    Vílchez JJ; Casanova B; Monte E
    Med Clin (Barc); 1996 Jan; 106(1):37-8. PubMed ID: 8750543
    [No Abstract]   [Full Text] [Related]  

  • 16. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
    Lundh H; Nilsson O; Rosén I; Johansson S
    Acta Neurol Scand; 1993 Aug; 88(2):136-40. PubMed ID: 8213058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
    Oh SJ; Kim DS; Kwon KH; Tseng A; Mussell H; Claussen GC
    Ann N Y Acad Sci; 1998 May; 841():827-31. PubMed ID: 9668337
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J; Mills KR
    Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
    Smith AG; Wald J
    Neurology; 1996 Apr; 46(4):1143-5. PubMed ID: 8780107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The treatment of the Eaton-Lambert myasthenic syndrome with 3,4-diaminopyridine].
    Casanova B; Vílchez JJ; Rubio P
    Rev Clin Esp; 1993 Apr; 192(7):354-5. PubMed ID: 8388576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.